ApoE Receptor Biology and Neurodegeneration

ApoE 受体生物学和神经退行性变

• 批准号: 8500085
• 负责人: MARY JO LADU
• 金额: $ 175.04万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-15 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8500085
• 关键词: Adaptor Signaling Protein; Address; Adult; Affect; Affinity; Alzheimer' s Disease; Alzheimer' s disease risk; Amyloid beta-Protein; Amyloid beta-Protein Precursor; Animals; Apolipoprotein E; Apolipoproteins; Automobile Driving; Behavior; Behavioral; Binding; Biochemistry; Biological Assay; Biology; Brain; Cell surface; Cellular biology; Chicago; Cholesterol; Cognitive; Collaborations; Communication; Coupled; Data; Disease; Disease Association; Dominant-Negative Mutation; E protein; Electrophysiology (science); Endocytosis; Event; Exons; Experimental Models; Family; Family member; Florida; Generations; Genes; Genetic; Genetic Variation; Goals; Haplotypes; Human; Illinois; Individual; Kentucky; LDL Cholesterol Lipoproteins; LDL-Receptor Related Protein 1; Length; Life Cycle Stages; Link; Low Density Lipoprotein Receptor; Measurable; Measures; Mediating; Memory; Metabolism; Molecular; Molecular Biology; Molecular and Cellular Biology; Mus; Nerve Degeneration; Neuraxis; Neuroglia; Neuronal Plasticity; Neurons; Pathogenesis; Pathologic Processes; Pathway interactions; Patients; Physiological; Physiology; Plasma; Platelet-Derived Growth Factor; Process; Production; Property; Protein Biochemistry; Protein Isoforms; Proteolysis; Proteolytic Processing; RNA Splicing; Reagent; Receptor Activation; Receptor Gene; Recycling; Regulation; Relative (related person); Research Personnel; Role; Scientist; Signal Transduction; Single Nucleotide Polymorphism; Site; Source; Synaptic plasticity; Testing; Therapeutic; Transgenic Animals; Transgenic Mice; Transgenic Organisms; Universities; Variant; Washington; Work; aged; amyloid precursor protein processing; apolipoprotein E receptor 2; apolipoprotein E-1; apolipoprotein E-4; base; design; extracellular; functional outcomes; gamma secretase; genetic risk factor; in vivo; insight; interdisciplinary approach; interest; memory process; mouse model; neurobehavior; neuropathology; neurotoxicity; novel; programs; promoter; protein protein interaction; receptor; receptor binding; receptor expression; receptor function; research study; secretase; symposium; synaptic function; trafficking; uptake

The most important genetic risk factor for Alzheimer's disease (AD) is the APOE gene. APOE encodes the apolipoprotein E (apoE) protein, the main apolipoprotein in the central nervous system (CNS). ApoE interacts with the family of low density lipoprotein receptors, and these apoE receptors are expressed by neurons and glia. Thus, apoE receptors regulate apoE metabolism and mediate the effects of apoE on neuronal signaling, APP processing, neurotoxicity, and synaptic function. The goal of this Program is to take advantage of the overlapping interests and diverse expertise of five scientists examining the biology of apoE and apoE receptors in the CNS. The Aims of this Program are to define the expression and function of apoE receptors in the CNS, and how their functions are regulated by the three apoE isoforms and cellular proteolytic events. These projects also include an examination of the generation and function of soluble receptors. In Project 1, Dr. LaDu will examine how apoE receptors and beta-amyloid peptide mediate the metabolism of the 3 human apoE isoforms. In Project 2, Dr. Estus will test whether genetic variations within apoE receptor genes alter their functions and define whether these variations affect the risk of AD. In Project 3, Dr. Bu will define factors that affect the trafficking and processing of one of these receptors, LRP, and determine how LRP affects the amyloid precursor protein. In Project 4, Dr. Rebeck will examine another brain apoE receptor, ApoER2, and determine how its processing is regulated, and define the fate of soluble apoE receptors. In Project 5, Dr. Weeber will determine the mechanisms of apoE-dependent modulation of synaptic plasticity and in vivo effects of apoE receptor activation on neurobehavior and neuroplasticity. THE CORES INCLUDE: A) Administrative Core (for fiscal management, maintaining good communications between the five sites and overseeing a yearly symposium on apoE and apoE receptors); B) Molecular Cell Biology Core (for conducting standardized assays of apoE, apoE receptors, and Abeta, for developing, characterizing and distributing new common reagents, and for generating new transgenic mouse models as part of this Program); and C) Transgenic Core (all mice are maintained at Taconic, for distributing transgenic mouse models of AD and mice with altered levels of apoE receptors). This Program will thus provide new and valuable information about how apoE and apoE receptors affect the pathogenesis of Alzheimer's disease.

阿尔茨海默病(AD)最重要的遗传风险因素是APOE基因。载脂蛋白E编码载脂蛋白E(ApoE)，是中枢神经系统(CNS)中的主要载脂蛋白。载脂蛋白E与低密度脂蛋白受体家族相互作用，这些载脂蛋白E受体由神经元和胶质细胞表达。因此，apoE受体调节apoE代谢，并介导apoE对神经元信号、APP处理、神经毒性和突触功能的影响。该计划的目标是利用五位科学家在研究中枢神经系统载脂蛋白E和载脂蛋白E受体的生物学方面的重叠兴趣和不同的专业知识。本计划的目的是确定载脂蛋白E受体在中枢神经系统中的表达和功能，以及载脂蛋白E的三种亚型和细胞蛋白分解事件如何调节其功能。这些项目还包括对可溶性受体的产生和功能的检查。在项目1中，拉杜博士将研究载脂蛋白E受体和β-淀粉样肽如何调节人类载脂蛋白E三种亚型的新陈代谢。在项目2中，埃斯特斯博士将测试载脂蛋白E受体基因内的遗传变异是否会改变它们的功能，并确定这些变异是否会影响AD的风险。在项目3中，布博士将定义影响其中一种受体LRP的运输和加工的因素，并确定LRP如何影响淀粉样前体蛋白。在项目4中，丽贝克博士将研究另一种大脑载脂蛋白E受体ApoER2，并确定其过程是如何调节的，并确定可溶的载脂蛋白E受体的命运。在项目5中，Weeber博士将确定apoE依赖的突触可塑性调节机制，以及apoE受体激活对神经行为和神经可塑性的体内影响。 这些核心包括：A)管理核心(负责财务管理，保持五个站点之间的良好沟通，并监督关于载脂蛋白E和载脂蛋白E受体的年度研讨会)；B)分子细胞生物学核心(用于进行载脂蛋白E、载脂蛋白E受体和Abeta的标准化分析，用于开发、表征和分发新的通用试剂，并作为该计划的一部分，用于产生新的转基因小鼠模型)；以及C)转基因核心(所有小鼠均保留在Taconic，用于分发载脂蛋白E受体水平改变的转基因AD小鼠模型)。因此，该计划将提供关于载脂蛋白E和载脂蛋白E受体如何影响阿尔茨海默病发病机制的新的有价值的信息。

项目成果

Longitudinal trajectories of cholesterol from midlife through late life according to apolipoprotein E allele status.

• DOI: 10.3390/ijerph111010663
• 发表时间: 2014-10-16
• 期刊: International journal of environmental research and public health
• 作者: Downer B;Estus S;Katsumata Y;Fardo DW
• 通讯作者: Fardo DW

Apolipoprotein E and LRP1 Increase Early in Parkinson's Disease Pathogenesis.

载脂蛋白 E 和 LRP1 在帕金森病发病机制早期增加。

• DOI: 10.1016/j.ajpath.2011.07.021
• 发表时间: 2011
• 期刊: The American journal of pathology
• 作者: Wilhelmus,MichaMM;Bol,JohnGJM;VanHaastert,EliseS;Rozemuller,AnnemiekeJM;Bu,Guojun;Drukarch,Benjamin;Hoozemans,JeroenJM
• 通讯作者: Hoozemans,JeroenJM

Differential allelic representation (DAR) identifies candidate eQTLs and improves transcriptome analysis.

差异等位基因表达 (DAR) 识别候选 eQTL 并改进转录组分析。

• DOI: 10.1101/2023.03.02.530865
• 发表时间: 2023
• 期刊: bioRxiv : the preprint server for biology
• 作者: Baer,Lachlan;Barthelson,Karissa;Postlethwait,John;Adelson,David;Pederson,Stephen;Lardelli,Michael
• 通讯作者: Lardelli,Michael

Reelin supplementation recovers sensorimotor gating, synaptic plasticity and associative learning deficits in the heterozygous reeler mouse.

reelin补充恢复了杂合子卷轴小鼠中的感觉运动门控，突触可塑性和关联学习缺陷。

• DOI: 10.1177/0269881112463468
• 发表时间: 2013-04
• 期刊: Journal of psychopharmacology (Oxford, England)
• 作者: Rogers JT;Zhao L;Trotter JH;Rusiana I;Peters MM;Li Q;Donaldson E;Banko JL;Keenoy KE;Rebeck GW;Hoe HS;D'Arcangelo G;Weeber EJ
• 通讯作者: Weeber EJ

Isoform of APOE with retained intron 3; quantitation and identification of an associated single nucleotide polymorphism.

• DOI: 10.1186/1750-1326-5-34
• 发表时间: 2010-09-07
• 期刊: Molecular neurodegeneration
• 影响因子: 15.1
• 作者: Dieter LS;Estus S
• 通讯作者: Estus S